Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

South Korean Government Moves To Produce Hospital Marketing Specialists To Raise Local Standards

This article was originally published in PharmAsia News

Executive Summary

SEOUL - On the heels of a recent government announcement that it will further strengthen the nation's biologics, medical devices and global health care areas, the Ministry for Health, Welfare and Family Affairs is moving to train and produce what it calls "hospital marketing specialists" from local universities

You may also be interested in...



Korea Targets Biologics, Devices, Health Care Among Economic Growth Projects For Next Decade

SEOUL - South Korean President Lee Myung-bak named "17 new growth engines" at a science and technology council meeting at his office in Seoul Jan. 13. Expected to spearhead the country's economic growth for the next 10 years, of those 17 economic growth engines, the Korean government targeted biologics, medical devices and global health care among the national priorities

More Than Half Of Trials Conducted In South Korea Led By Pfizer

SEOUL - The number of clinical trials Pfizer Korea conducted in South Korea last year rose sharply to 93 cases from 75 cases in 2007, a result of Pfizer's move to conduct more of its clinical trials in South Korea

Bayer Schering Strengthens Presence In South Korea

SEOUL - Bayer Schering Pharma plans to upgrade its current seventh position in South Korea's pharma market to become one of three leading multinational companies in coming years, Bayer execs told reporters at a Nov. 27 press conference in Seoul

Latest Headlines
See All
UsernamePublicRestriction

Register

SC069894

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel